• This record comes from PubMed

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

. 2023 Aug 20 ; 41 (24) : 4014-4024. [epub] 20230622

Language English Country United States Media print-electronic

Document type Randomized Controlled Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid37348019

PURPOSE: Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant, estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer (aBC). PATIENTS AND METHODS: In AMEERA-3 (ClinicalTrials.gov identifier: NCT04059484), an open-label, worldwide phase II trial, patients with ER+/HER2- aBC who progressed in the (neo)adjuvant or advanced settings after not more than two previous lines of endocrine therapy (ET) were randomly assigned 1:1 to amcenestrant or single-agent endocrine treatment of physician's choice (TPC), stratified by the presence/absence of visceral metastases, previous/no treatment with cyclin-dependent kinase 4/6 inhibitor, and Eastern Cooperative Oncology Group performance status (0/1). The primary end point was progression-free survival (PFS) by independent central review, compared using a stratified log-rank test (one-sided type I error rate of 2.5%). RESULTS: Between October 22, 2019, and February 15, 2021, 290 patients were randomly assigned to amcenestrant (n = 143) or TPC (n = 147). PFS was numerically similar between amcenestrant and TPC (median PFS [mPFS], 3.6 v 3.7 months; stratified hazard ratio [HR], 1.051 [95% CI, 0.789 to 1.4]; one-sided P = .643). Among patients with baseline mutated ESR1; (n = 120 of 280), amcenestrant numerically prolonged PFS versus TPC (mPFS, 3.7 v 2.0 months; stratified HR, 0.9 [95% CI, 0.565 to 1.435]). Overall survival data were immature but numerically similar between groups (HR, 0.913; 95% CI, 0.595 to 1.403). In amcenestrant versus TPC groups, treatment-emergent adverse events (any grade) occurred in 82.5% versus 76.2% of patients and grade ≥3 events occurred in 21.7% versus 15.6%. CONCLUSION: AMEERA-3 did not meet its primary objective of improved PFS with amcenestrant versus TPC although a numerical improvement in PFS was observed in patients with baseline ESR1 mutation. Efficacy and safety with amcenestrant were consistent with the standard of care for second-/third-line ET for ER+/HER2- aBC.

See more in PubMed

Sung H, Ferlay J, Siegel RL, et al. : Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021 PubMed

National Cancer Institute Surveillance , Epidemiology, and End Results Program: Cancer stat facts: Female breast cancer subtypes. https://seer.cancer.gov/statfacts/html/breast-subtypes.html

American Cancer Society : Breast Cancer Facts & Figures 2019-2020. Atlanta, GA, American Cancer Society, Inc, 2019

Cardoso F, Paluch-Shimon S, Senkus E, et al. : 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623-1649, 2020 PubMed PMC

Anurag M, Ellis MJ, Haricharan S: DNA damage repair defects as a new class of endocrine treatment resistance driver. Oncotarget 9:36252-36253, 2018 PubMed PMC

Razavi P, Chang MT, Xu G, et al. : The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell 34:427-438 e6, 2018 PubMed PMC

National Comprehensive Cancer Network : Breast cancer (version 2.2022). https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf

Patel HK, Bihani T: Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacol Ther 186:1-24, 2018 PubMed

AstraZeneca : FASLODEX (fulvestrant) injection, for intramuscular use [prescribing information]. https://www.azpicentral.com/faslodex/faslodex.pdf

Robertson JFR, Bondarenko IM, Trishkina E, et al. : Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): An international, randomised, double-blind, phase 3 trial. Lancet 388:2997-3005, 2016 PubMed

Cristofanilli M, Turner NC, Bondarenko I, et al. : Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): Final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425-439, 2016 PubMed

Slamon DJ, Neven P, Chia S, et al. : Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36:2465-2472, 2018 PubMed

Sledge GW, Jr, Toi M, Neven P, et al. : MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35:2875-2884, 2017 PubMed

Fribbens C, O'Leary B, Kilburn L, et al. : Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 34:2961-2968, 2016 PubMed

Hopkins U, Arias CY: Large-volume IM injections: A review of best practices. Oncol Nurse Advis 2013:32-37, 2013

Ohno S, Rai Y, Iwata H, et al. : Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: Results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 21:2342-2347, 2010 PubMed

Pritchard KI, Rolski J, Papai Z, et al. : Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 123:453-461, 2010 PubMed

van Kruchten M, de Vries EG, Glaudemans AW, et al. : Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer. Cancer Discov 5:72-81, 2015 PubMed

Toy W, Weir H, Razavi P, et al. : Activating ESR1 mutations differentially affect the efficacy of ER antagonists. Cancer Discov 7:277-287, 2017 PubMed PMC

Bardia A, Chandarlapaty S, Linden HM, et al. : AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer. Nat Commun 13:4116, 2022 PubMed PMC

Eisenhauer EA, Therasse P, Bogaerts J, et al. : New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247, 2009 PubMed

Hamilton EP, Oliveira M, Banerji U, et al. : A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer. J Clin Oncol 38, 2020. (suppl; abstr 1024) PubMed

Hamilton EP, Wang JS, Pluard TJ, et al. : Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. J Clin Oncol 39, 2021. (suppl; abstr 1018)

Lim E, Jhaveri KL, Perez-Fidalgo JA, et al. : A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer. J Clin Oncol 38, 2020. (suppl; abstr 1023)

Oliveira M, Pominchuck D, Nowecki Z, et al. : Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial. Cancer Res 83, 2023. (suppl; abstr GS3-02)

Bidard F-C, Kaklamani VG, Neven P, et al. : Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from the randomized phase III EMERALD trial. J Clin Oncol 40:3246-3256, 2022 PubMed PMC

Martin Jimenez M, Lim E, Chaves MacGregor M, et al. : Giredestrant (GDC-9545) vs physician choice of endocrine monotherapy (PCET) in patients (pts) with ER+, HER2– locally advanced/metastatic breast cancer (LA/mBC): Primary analysis of the phase 2, randomised, open-label acelERA BC study. Ann Oncol 33:S633-S634, 2022. (suppl 7; abstr 211MO)

Shimoi T, Sagara Y, Hara F, et al. : First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A systematic review and meta-analysis. Breast Cancer 27:340-346, 2020 PubMed PMC

Zhang J, Huang Y, Wang C, et al. : Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis. Medicine (Baltimore) 96:e7846, 2017 PubMed PMC

Bidard F-C, Hardy-Bessard A-C, Bachelot T, et al. : Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating ESR1 mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial. Cancer Res 82, 2022. (7, suppl; abstr GS3-05)

Brett JO, Spring LM, Bardia A, et al. : ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res 23:85, 2021 PubMed PMC

Spoerke JM, Gendreau S, Walter K, et al. : Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:11579, 2016 PubMed PMC

Turner NC, Swift C, Kilburn L, et al. : ESR1 mutations and overall survival on fulvestrant versus exemestane in advanced hormone receptor-positive breast cancer: A combined analysis of the phase III SoFEA and EFECT trials. Clin Cancer Res 26:5172-5177, 2020 PubMed

Martin M, Zielinski C, Ruiz-Borrego M, et al. : Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: A phase III randomised controlled trial-PEARL. Ann Oncol 32:488-499, 2021 PubMed

Turner NC, Kingston B, Kilburn LS, et al. : Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): A multicentre, multicohort, phase 2a, platform trial. Lancet Oncol 21:1296-1308, 2020 PubMed PMC

Stemline Therapeutics Inc. a Menarini Group Company: ORSERDU (elacestrant) for oral use (prescribing information). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217639s000lbl.pdf

Guardant Health receives FDA approval for Guardant360 CDx as companion diagnostic for Menarini Group’s ORSERDU for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer. News Release. Guardant Health, Inc, January 30, 2023. https://bit.ly/3HGF5hu

O'Leary B, Cutts RJ, Liu Y, et al. : The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial. Cancer Discov 8:1390-1403, 2018 PubMed PMC

Yardley DA, Noguchi S, Pritchard KI, et al. : Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 30:870-884, 2013 PubMed PMC

André F, Ciruelos E, Rubovszky G, et al. : Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 380:1929-1940, 2019 PubMed

Bardia A, Cortes J, Hurvitz SA, et al. : AMEERA-5: A randomized, double-blind phase 3 study of amcenestrant plus palbociclib versus letrozole plus palbociclib for previously untreated ER+/HER2- advanced breast cancer. Ther Adv Med Oncol 10.1177/17588359221083956 [epub ahead of print on March 15, 2022] PubMed DOI PMC

US Food and Drug Administration : Premenopausal women with breast cancer: Developing drugs for treatment. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/premenopausal-women-breast-cancer-developing-drugs-treatment

US Food and Drug Administration : Male breast cancer: Developing drugs for treatment. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/male-breast-cancer-developing-drugs-treatment

See more in PubMed

ClinicalTrials.gov
NCT04059484

Find record

Citation metrics

Archiving options